By Johnny Rice, Benzinga

Dr. Ann Childress and Shane Schaffer, Chairman & CEO of Cingulate (NASDAQ: CING), were recently guests on Benzinga’s All Access.

Cingulate is a biotechnology company developing drugs for a range of underserved conditions. The company has developed a proprietary technology called Precision Timed Release™ (PTR™). The technology allows a single pill to contain multiple doses of a drug, relieving the pill burden many people with chronic conditions suffer.

Cingulate says it will be submitting a New Drug Application within a year.

Watch the full interview here:

Featured photo by Thought Catalog on Unsplash.

Benzinga is a leading financial media and data provider, known for delivering accurate, timely, and actionable financial information to empower investors and traders.

This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice.

Benzinga

+1 877-440-9464

info@benzinga.com

http://www.benzinga.com

View source version on newsdirect.com: https://newsdirect.com/news/september-04-2024-09-00-am-eastern-340642620

This press release is distributed by News Direct. Blockchain Registration, Verification & Enhancement provided by NewsRamp™. The source URL for this press release is September 04, 2024 09:00 AM, Eastern.